Outpatient cervical ripening with intravaginal misoprostol

Area of Science:

• Obstetrics and Gynecology
• Reproductive Medicine

Background:

• Cervical ripening is crucial for initiating labor in term pregnancies.
• Outpatient management strategies aim to improve patient convenience and potentially reduce healthcare costs.

Purpose of the Study:

• To evaluate the efficacy of outpatient cervical ripening using misoprostol in initiating labor within 48 hours.
• To assess if outpatient misoprostol reduces the time from medication administration to delivery.

Main Methods:

• A randomized controlled trial involving uncomplicated singleton, vertex pregnancies at 41 weeks' gestation or later with a low Bishop score.
• Participants received either 25 mcg of intravaginal misoprostol or placebo, with repeat dosing at 24 hours if active labor was not achieved.
• Patients were monitored for 4 hours post-administration and discharged if not in active labor, returning for further assessment or admission if undelivered within 48 hours.

Main Results:

• Out of 60 enrolled patients, 27 received misoprostol and 33 received placebo.
• A significantly higher proportion of the misoprostol group (88.9%) entered active labor within 48 hours compared to the placebo group (16.7%) (P <.001).
• The mean time from initial dose to delivery was substantially shorter in the misoprostol group (36.9 hours) versus the placebo group (61.3 hours) (P <.001).

Conclusions:

• Intravaginal misoprostol is an effective method for outpatient cervical ripening.
• The study found no adverse effects, but further research is recommended to confirm the safety profile of this outpatient treatment regimen.